表紙
市場調查報告書

分析工具:癌症治療的蛋白激□抑制劑

Protein Kinase Inhibitors in Oncology: Analytical Tool

出版商 BioSeeker Group AB 商品編碼 166080
出版日期 內容資訊 英文
商品交期: 最快1-2個工作天內
價格
Back to Top
分析工具:癌症治療的蛋白激□抑制劑 Protein Kinase Inhibitors in Oncology: Analytical Tool
出版日期: 2018年12月05日內容資訊: 英文
簡介

本報告專注腫瘤治療領域的業務開發、事業及企業情報蒐集、臨床開發。對於想在這個越來越受矚目、快速發展領域中維持優勢的組織人員而言,這是必備的手冊。本報告無與倫比,將是您在進行蛋白激□抑制劑售後調查、蒐集情報時,相較競爭對手維持自身優勢、執行精準決策、進而拓展業績的一大助力。

本報告透過不斷審查蛋白激□抑制劑開發情況,實現提供最新情報的任務。

  • 契約和合作
  • 新技術/醫藥品 (來自專利、補助、各學會研究發表摘要等的情報)
  • 資金籌措/補助/IPO
  • 申請和核准
  • 臨床試驗最新發展和結果
  • 新啟動的臨床試驗
  • 全球各地舉辦的腫瘤學相關12個領導學會之報導*
  • 季度和年度報告

透過本報告,您可完全掌握該領域日常動向,並能綜合審視產品開發PIPELINE、評估競爭企業。透過各種因素,能夠特定、設定優先順序、引導出腫瘤治療領域商業機會或競爭企業相關科學評估。

  • 最新技術
  • 標靶新穎性
  • 最新研究成果
  • 早期和晚期階段PIPELINE
  • 生物標記/伴隨式診斷的開發
  • 締結合約或合作
  • 全球主要癌症學會的會議監督
  • 併用療法的選擇
  • 臨床試驗結果
  • 適應症選擇和擴大選擇
  • 既有藥物再開發的可能性

本報告網羅致力於1,668項蛋白激□抑制劑開發的508間企業及合作夥伴,其中940項正積極研發針對322種癌症標靶。您可保留本研究報告分析工具所獲得的數據或分析,並能將數據/圖表/表格以Excel/PDF等各種格式輸出,與您獨自蒐集的情報進行組合。

系統要求

  • 瀏覽器應用程式 (支援Internet Explorer、FireFox、Chrome、Safari)
  • 網路連接

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: BSG21823

Kinase-targeted cancer therapies became really big with imatinib (Gleevec), a landmark drug that has vastly improved the outcomes of patients with chronic myelogenous leukemia. With the human genome encoding 538 protein kinases and many of these kinases being associated with human cancer initiation and progression, this field carries a lot of promise for more treatment successes in the future.

Protein Kinase Inhibitors in Oncology: Analytical Tool is the must have handbook for any business developer, BI/CI operative or clinical developer who needs to be on top of this hot and fast moving area of oncology. This unique product is truly the only tool of its kind and is designed to give you a competitive edge in your PKI drug surveillance and intelligence, allowing you to power your decision making and advance your own interests.

Keeping you "In the know"

Simply put, our mission is to fuel your knowledge of oncology, to make you the first to know about very early technologies and startups, emerging clinical trial results, drug approvals and the ever-changing competitive landscape. Protein Kinase Inhibitors in Oncology: Analytical Tool achieves this by continuously scanning development in PKI and reporting:

  • Deals & Collaborations
  • New technologies/drugs (emerging from patents, grants, abstracts (see Conference Coverage) etc.)
  • Funding/Grants/IPOs
  • Filings & Approvals
  • Latest Clinical Trial Development & Results
  • Newly launched clinical trials
  • Conference Coverage of the world's twelve leading meetings in oncology*
  • Quarterly & Annual Reporting

This puts you in control of most, if not all, day-to-day developments in your field while also benefiting from one of the most comprehensive commercial pipeline review & competitive assessment tools available on the market today! Identify, prioritize, and lead scientific assessment of oncology opportunities and competition by multiple factors such as:

  • Emerging Technologies
  • Target Novelty
  • Recent Funding
  • Early & Late Stage Pipeline
  • Biomarker/Companion Diagnostic Development (featured below)
  • Entered Deals & Alliances
  • Conference surveillance of world leading cancer meetings (featured below)
  • Combination Therapy Choices (featured below)
  • Outcome of Clinical Trials
  • Indication Selection & Expansion Choices
  • Drug Repositioning Opportunities

For 20 years we have supported better decision making across the oncology drug development industry. Your Protein Kinase Inhibitors in Oncology: Analytical Tool is based on two decades of proven methodology and transforms your computer's desktop into a high capacity workbench within your area of choice. Even before launching this tool you have already eliminated the hundreds of hours of work needed to discover, process and piece together the thousands of sources that our team of oncology dedicated and highly experienced contents specialists have done on your behalf.

Your Protein Kinase Inhibitors in Oncology: Analytical Tool covers more than 508 companies plus partners who are today developing 1668 PKI drugs where of 940 are in active development in cancer across 322 different targets. Any data and/or analysis from the Analytical Tool is yours to keep and data/graphs/tables can be easily exported into Excel/PDF and various graphic formats for mixing with your own proprietary information.

Let our expertise work for you

With a simple point and click interface you can navigate the environment of current development, drill down into specific areas such as ongoing combination trials, biomarker analysis, selected scientific abstracts etc. and generate drug profiles, drug target profiles and company profiles (including Business Development & Licensing contacts). Any analysis generated by you is packed with presentation-ready graphs and tables to use in your reports and presentations.

Your key to access development at the world-leading cancer meetings

The Protein Kinase Inhibitors in Oncology: Analytical Tool is continuously updated according to twelve of the world's most influential meetings in oncology (AACR, ASCO, ASGCT, ASH, CMIT, EHA, EORTC-NCI-AACR, ESMO, SITC and BIO (International, Europe and Asia). If you are not able to attend any of the conference(s) in person, this Analytical Tool ensures that you are not missing out on the important take home messages you need to know about.

Run combination therapy analysis like no other

The Protein Kinase Inhibitors in Oncology: Analytical Tool delivers comprehensive combination therapy analysis, allowing you to analyze combination therapies from multiple perspectives; from a single drug to virtually any cross section of oncology drugs of interest.

Unparalleled biomarker surveillance

We also provide an outstanding oncology clinical biomarker surveillance & analysis, highlighting clinical phenotyping and patient stratification in trials. This analysis is based on our monitoring of the presence and usage of more than 1,000 biomarkers across tens of thousands of cancer clinical trials.

Support and inspiration at your finger-tips

You also have access to a great selection of How-to Training Videos showing best practice approaches to aspects such as competitive pipeline analysis right through to many real world case examples put forward by other users of our Analytical Tools.

A tool to grow with and keep you informed

Unlike a static report which just represents a particular snapshot in time, all of the Analytical Tools come with one year of online access to twice-weekly updates in both contents and features, pipeline alerts and online support etc. You can choose to renew your access to these updates and support on a yearly basis or go over to our industry leading full service platform covering all oncology drug development, 1stOncology.

System Requirements

  • Browser Application (Supports: Internet Explorer, FireFox, Chrome and Safari))
  • Internet access
Back to Top